tradingkey.logo
tradingkey.logo
Search

Adaptive Biotechnologies Corp

ADPT
Add to Watchlist
22.336USD
+0.886+4.13%
Market hours ETQuotes delayed by 15 min
3.57BMarket Cap
LossP/E TTM

TradingKey Stock Score of Adaptive Biotechnologies Corp

Currency: USD Updated: 2026-06-30

Key Insights

Adaptive Biotechnologies Corp's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Adaptive Biotechnologies Corp's Score

Industry at a Glance

Industry Ranking
11 / 387
Overall Ranking
45 / 4569
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Adaptive Biotechnologies Corp Highlights

StrengthsRisks
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 62.66% year-on-year.
Undervalued
The company’s latest PE is -66.85, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 151.51M shares, decreasing 8.01% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 30.08M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.99.

Analyst Rating

Based on 8 analysts
Buy
Current Rating
20.500
Target Price
-4.21%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Adaptive Biotechnologies Corp?

The TradingKey Stock Score provides a comprehensive assessment of Adaptive Biotechnologies Corp based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Adaptive Biotechnologies Corp’s performance and outlook.

How do we generate the financial health score of Adaptive Biotechnologies Corp?

To generate the financial health score of Adaptive Biotechnologies Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Adaptive Biotechnologies Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Adaptive Biotechnologies Corp.

How do we generate the company valuation score of Adaptive Biotechnologies Corp?

To generate the company valuation score of Adaptive Biotechnologies Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Adaptive Biotechnologies Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Adaptive Biotechnologies Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Adaptive Biotechnologies Corp.

How do we generate the earnings forecast score of Adaptive Biotechnologies Corp?

To calculate the earnings forecast score of Adaptive Biotechnologies Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Adaptive Biotechnologies Corp’s future.

How do we generate the price momentum score of Adaptive Biotechnologies Corp?

When generating the price momentum score for Adaptive Biotechnologies Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Adaptive Biotechnologies Corp’s prices. A higher score indicates a more stable short-term price trend for Adaptive Biotechnologies Corp.

How do we generate the institutional confidence score of Adaptive Biotechnologies Corp?

To generate the institutional confidence score of Adaptive Biotechnologies Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Adaptive Biotechnologies Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Adaptive Biotechnologies Corp.

How do we generate the risk management score of Adaptive Biotechnologies Corp?

To assess the risk management score of Adaptive Biotechnologies Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Adaptive Biotechnologies Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Adaptive Biotechnologies Corp.